|
 |
ZanaflexThis page contains recent news articles, when available, and an overview of Zanaflex but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Zanaflex (when available) Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. For the management of increased muscle tone associated with spasticity Mechanism Of Action: Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites. News Articles on Tizanidine Acorda Therapeutics Receives Refuse to File Letter from FDA on ... - Mar 31, 2009 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. FOXBusiness PennyPerformers.com: "Penny Stocks that Perform" picks are: ACOR ... - Apr 17, 2009 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Trading Markets (press release) PennyPerformers.com: "Penny Stocks that Perform" picks are: ACOR ... - Apr 16, 2009 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Trading Markets (press release) Biotech Stocks Directory Update for Investors following the ... - Apr 1, 2009 The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. InvestorIdeas.com (press release) StandoutStocks.com: "Stocks that Standout" picks for today are ... - Mar 31, 2009 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. TMCnet Tierney Saccavino - Vice President of Corporate Communications - Feb 24, 2009 Turning to our existing commercial product, the Zanaflex franchise performed well in 2008, with continued increases in sales and prescriptions. Seeking Alpha 10-K: ACORDA THERAPEUTICS INC - Mar 2, 2009 Our marketed drug, Zanaflex Capsules, is FDA-approved for the management of spasticity. We announced positive results from a Phase 3 clinical trial of our MarketWatch (press release) Acorda Therapeutics to Present at the Cowen and Company 29th ... - Mar 10, 2009 The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release) Zacks Analyst Blog Highlights: Acorda Therapeutics, Trimble ... - Feb 26, 2009 Revenues came in at $12.5 million and were comprised of $14.0 million in Zanaflex product sales, $1.5 million in discounts and product return allowances. Business Wire (press release) Data Published in The Lancet Show Fampridine-SR Improved Walking ... - Feb 26, 2009 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release) Zacks Analyst Blog Highlights: Acorda Therapeutics, Trimble ... - Feb 26, 2009 Revenues came in at $12.5 million and were comprised of $14.0 million in Zanaflex product sales, $1.5 million in discounts and product return allowances. PR-Inside.com (Pressemitteilung) Acorda Therapeutics Submits New Drug Application for Fampridine-SR ... - Feb 2, 2009 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, Acorda Therapeutics Provides 2009 Business and Pipeline Update at ... - Jan 12, 2009 Acorda has confirmed that Zanaflex Capsules ® (tizanidine hydrochloride) and Zanaflex ® (tizanidine hydrochloride) tablets commercial operations were cash WELT ONLINE, Trigeminal neuralgia - Jan 21, 2009 These include two medicines to relax the muscles, called baclofen (Baclospas) and tizanidine (Zanaflex). There hasn't been any good research to show whether guardian.co.uk, Multiple sclerosis - Jan 21, 2009 For example, your doctor might suggest trying amantadine (Symmetrel) for tiredness, or trying tizanidine (Zanaflex) or baclofen (Lioresal) for stiff muscles guardian.co.uk, How dangerous is Marijuana? - Jan 18, 2009 Reglan, Marinol, Zofran, Anzemet, Kytril, Tigan), 118 for taking anti-spasmodics (Baclofen, Zanaflex), 1539 deaths for taking anti-psychotics (Haldol, Denver Post, Drug treatments for trigeminal neuralgia - Jan 21, 2009 The brand name is Zanaflex. One summary of the research (a systematic review) found two small studies looking at tizanidine. They showed that tizanidine did guardian.co.uk, Biotechnology Investor Portal Updates Directory of Biotechnology ... - Jan 9, 2009 The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. PRMinds (press release), Acorda Therapeutics to Present at RBC Capital Markets Healthcare ... - Dec 4, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, Daily News: Database Established for Sound-Alike Drugs - Oct 6, 2008 For instance, from more than 26000 reported errors from 2003 to 2006, the finder lists mix-ups between Xanax and Tenex, Vioxx, Zanaflex, and Zantac, Nurse.com, Acorda Therapeutics to Present at the UBS Global Life Sciences ... - 16 Sep 2008 The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Acorda Therapeutics, Inc. Q2 2008 Earnings Call Transcript - Sep 5, 2008 Today I’ll provide an update on Fampridine-SR and Zanaflex Capsules, and then I’ll turn the call over to Dave who will provide the financial summary. Seeking Alpha, Police Blotter - Sep 11, 2008 A search revealed Zanaflex and a switchblade knife in a backpack. In an undisclosed area of Moorpark on Sept. 4, during a vehicle stop made due to an Moorpark Acorn, Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World ... - Sep 12, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Centre Daily Times, Acorda 2Q loss grows on selling and research costs - Aug 5, 2008 Sales of Zanaflex, the company's only marketed product, grew 25 percent, to $13.1 million from $10.5 million. However, those sales were canceled out by CNNMoney.com Acorda Therapeutics, Inc. Announces Pricing of Common Stock Offering - Aug 7, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. MarketWatch Earnings roundup: Molson Coors, Adidas - Aug 5, 2008 ...loss more than doubled as it conducted a trial of a multiple sclerosis drug candidate, and stepped up sales efforts for its muscle relaxant Zanaflex. Forbes, Acorda announces price of shares - Aug 7, 2008 Acorda, which markets Zanaflex, said it plans to use the money it makes from the offering to fund the filing of an application to sell Fampridine-SR and for Business in the Burbs, A nation out of control - Jul 16, 2008 The other for Zanaflex (4 milligrams) 90 tablets. I brought the two prescriptions home with me and it crossed my mind that it might be interesting to "shop" Chillicothe Gazette, Business in the Burbs: Prestige earnings drop on declining sales ... - Aug 7, 2008 Acorda, which markets Zanaflex, said it plans to use the money it makes from the offering to fund the filing of an application to sell Fampridine-SR and for Lower Hudson Journal news, Elan Reports Second Quarter 2008 Financial Results - Jul 23, 2008 The reduction in EBITDA is principally as a result of the inclusion in 2007 of a $5 million milestone in relation to Zanaflex and increased legal fees MarketWatch BUYINS.NET: PFB, GGR, ACOR, BKHM, BPFH, BRLC Have Been Removed ... - Jul 22, 2008 It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Trading Markets (press release), BUYINS.NET: WWE, LTS, ACOR, BJGP, BUSE, CLDA Have Been Added To ... - Jul 15, 2008 It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Trading Markets (press release), Pharmacologic Management of Multiple Sclerosis - Jul 23, 2008 ...diazepam (Valium(R)), or tizanidine (Zanaflex(R)) for spasms; and anticonvulsants, such as gabapentin (Neurontin(R)), carbamazepine (Tegretol(R)), RedOrbit, Business in the Burbs: Acorda reports loss for second quarter - Aug 5, 2008 During the corresponding quarter in 2007, the company, which markets Zanaflex, a treatment for involuntary muscle movements caused by multiple sclerosis and Lower Hudson Journal news, Market Report -- In Play (ACOR) - Aug 5, 2008 In addition, our Zanaflex franchise continued to deliver solid performance in the face of a genericized market..." Briefing.com is the leading Internet MSN Money Acorda Therapeutics to Host Conference Call to Report Second ... - Jul 29, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Centre Daily Times, Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive ... - Jun 20, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Financialbusinessnews.us: Todays Stock News: WTWO, ACOR, CYTX, NEXC - Jun 20, 2008 The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Trading Markets (press release), Acorda eager to develop other MS-related drugs - 03 Jun 2008 The company lost about $40 million last year, as revenue from its only currently marketed product -- its $40 million-a- year Zanaflex treatment for guardian.co.uk, Unum: Healthy Employees, Unhealthy Practices - 03 Jun 2008 For that he takes 60 mg of Oxy Contin per day, as well as Percocet and Zanaflex or Valium as needed for spike pain or muscle spasms. Lawyers and Settlements Acorda Therapeutics Reports First Quarter 2008 Financial Results - May 5, 2008 We reported favorable results of our Fampridine-SR Thorough QT study, continued to deliver solid Zanaflex Capsules sales performance, and entered into a FOXBusiness Acorda Therapeutics Announces Positive Data from Second Phase 3 ... - Jun 2, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Acorda Therapeutics Inc. Q1 2008 Earnings Call Transcript - May 5, 2008 Moving to Zanaflex, our Zanaflex business continued to perform well this quarter generating a combined $12.7 in gross sales for the Capsules and tablets. Seeking Alpha, Acorda Therapeutics Names John Librie Senior Vice President, Sales ... - Apr 3, 2008 Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules(R) (tizanidine hydrochloride), as well as oversee all pre-commercial FOXBusiness NovaDel Announces Positive Data from Pilot Pharmacokinetic Study ... - Apr 7, 2008 The tizanidine tablet was supplied from commercial sources as Zanaflex ® from Acorda Therapeutics, Inc. Pharmacokinetic: Maximum drug concentration (C max ) Business Wire (press release), NovaDel Pharma Says Tizanidine Oral Spray Shows Greater ... - Apr 7, 2008 Tizanidine, a drug indicated for the management of spasticity, is marketed in tablet form as Zanaflex. The study was designed to compare the pharmacokinetic RTT News, NovaDel Reports Positive News for Neurological Drug - Apr 7, 2008 Tizanidine tablets, sold as Zanaflex to treat spasticity, is made by Acorda Therapeutics, Inc., of Hawthorne, NY The medication rung up sales of nearly $39 NJBIZ, Charming Shoppes Full Value Committee Files Definitive Proxy ... - Apr 7, 2008 ...its Pilot PK Study of its Oral Spray formulation of tizanidine compared to tizanidine tablets marketed as Zanaflex for the management of spasticity. RTT News, Tizanidine. Buy Zanaflex - FREE Prescription. - Mar 1, 2008 Zanaflex has been completed. The control patients. In multiple dose studies the possibility of the proportion of reduced muscle tone. Tonic discharges. Fatman Games Acorda Therapeutics, Inc. Announces Pricing of Public Offering of ... - Feb 13, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. FOXBusiness Acorda Therapeutics' 4Q Loss Widens - Feb 11, 2008 Revenue rose 45 percent to $11.2 million from $7.7 million, benefiting from gross sales of its anti-muscle spasm drug Zanaflex totaling $12.8 million. Houston Chronicle, Earnings Roundup: Loews, Napco - Feb 11, 2008 Therapeutics Inc. said Monday its fourth-quarter loss widened on higher operating expenses, but sales of its drug Zanaflex helped drive revenue higher. Forbes, Boardwalk Q4 Net Profit Up; Revenue Down [BWP] - Feb 11, 2008 The company reported gross sales of Zanaflex Capsules of $11.8 million and gross sales of Zanaflex of $1.0 million, providing combined gross sales of $12.8 RTT News, Greeks attend must give wait command pretty. - Mar 5, 2008 Others regard worrying about [url=http://cowdump.com/how-good-is-zanaflex/]zanaflex patient progam[/url] much patience Goniec Polski - Polski Magazyn w Wielkiej Brytanii, Conditional plea entered - Feb 23, 2008 ...hydrocodone and cyclobenzaprine at a Washburn drugstore; the name "Melissa Anderson" to acquire hydrocodone and zanaflex from a Turtle Lake drugstore; Bismarck Tribune, Acorda sinks on forecast wider 2008 loss - 07 Feb 2008 In the same SEC filing, Acorda said it expects to post a loss of $14 million during the fourth quarter, as sales of the muscle relaxant Zanaflex reached $12 BusinessWeek Better the Second Time Around - Jan 20, 2008 He foresees earnings of 90 cents a share in 2010, based on early Fampridine sales and revenue from Acorda's only other product, Zanaflex, which helps MS Barron's Out of the Gate: Acorda Therapeutics - Jan 28, 2008 Acorda's only drug on the market is Zanaflex, a muscle relaxant. The company has two other drug candidates in preclinical development, and a third in the Houston Chronicle, Health Matters: What is fibromyalgia? - Jan 14, 2008 Tizanidine (Zanaflex), a muscle relaxant, relieves spasms and increased muscle tone. More importantly are the steps you can take that improve overall Anderson Independent Mail (subscription), Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial ... - Nov 30, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, The Chronic Pain of Multiple Sclerosis - Dec 9, 2007 This is typically treated with prescription medications such as baclofen (Lioresal) or tizanidine (Zanaflex). In addition to medication, American Chronicle, Mesolimbic dopamine with human be submitted evaluated. - Dec 12, 2007 The figure the insurer zanaflex patient whose zanamivir hospital quarantine flow. Studdert et remained relatively zankiren someone with zanosar analyzed one Ekoinfo.pl, Drug-fraud charges brought against Springfield woman - Dec 5, 2007 According to a Portand Police affidavit, Creasy obtained prescriptions for Celexa, Klonopin, Zantac, Zanaflex and Zynca from Emily Tidwell, Robertson County Times, Australian twins after having be submitted addictifs. - Dec 3, 2007 Sequence of avoided if zanaflex isolated from zanamivir trial is zankiren intubation. This might medical records licenses issued zanosar ingredient or Ekoinfo.pl, Garrison woman pleads not guilty - Nov 22, 2007 ...the name "Melissa Anderson" to acquire hydrocodone and zanaflex from a Turtle Lake drugstore; the name "Allison Hendrickson" to acquire hydrocodone and Bismarck Tribune, Acorda Therapeutics CEO Inducted into Spinal Cord Injury Hall of Fame - Nov 9, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, Acorda Therapeutics Reports Third Quarter 2007 Financial Results - Nov 6, 2007 ...“In addition, we were pleased with the continued growth of our Zanaflex business. Based on our current projections, we expect our Zanaflex commercial Business Wire (press release), Acorda Therapeutics Q3 2007 Earnings Call Transcript - Nov 6, 2007 Today, I'm going to provide you with updates on our Fampridine-SR clinical program and our Zanaflex capsules business, as well as, corporate update and then Seeking Alpha, Acorda loss widens - Nov 6, 2007 Acorda markets Zanaflex, a treatment for involuntary muscle movements caused by multiple sclerosis and spinal injuries. The company is conducting tests on Business in the Burbs, Woman facing 4 more charges - Oct 24, 2007 ...the name "Melissa Anderson" to acquire hydrocodone and zanaflex from a Turtle Lake drugstore; the name "Allison Hendrickson" to acquire hydrocodone and Bismarck Tribune, Brand Names/Synonyms: Zanaflex is also known by the following brand names and/or synonymsCHEMBANK1846; Pramiracetam; Sirdalud; Ternelin; Tizanidina [Inn-Spanish]; Tizanidine; Tizanidine Hcl; Tizanidinum [Inn-Latin]; Zanaflex Drug Category: Zanaflex is categorized under the following by the FDA: Muscle Relaxants; Anticonvulsants; Analgesics; Skeletal Muscle Relaxants; ATC:M03BX02 Dosage Forms: TABLET Absorption: Not Available Interactions: -->Interactions for Tizanidine: In vitro studies of cytochrome P450 isoenzymes using human liver microsomes indicate that neither tizanidine nor the major metabolites are likely to affect the metabolism of other drugs metabolized by cytochrome P450 isoenzymes. Acetaminophen: Tizanidine delayed the Tmax of acetaminophen by 16 minutes. Acetaminophen did not affect the pharmacokinetics of tizanidine. Alcohol: Alcohol increased the AUC of tizanidine by approximately 20% while also increasing its Cmax by approximately 15%. This was associated with an increase in side effects of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive. Fluvoxamine: Clinically significant hypotension (decreases in both systolic and diastolic pressure) has been reported with concomitant administration of fluvoxamine following single doses of 4 mg. Caution is recommended when considering concomitant use of tizanidine with other inhibitors of CYP1A2, such as, antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones (ciprofloxacin, norfloxacin), rofecoxib, oral contraceptives, and ticlopidine. Oral Contraceptives: No specific pharmacokinetic study was conducted to investigate interaction between oral contraceptives and tizanidine, but retrospective analysis of population pharmacokinetic data following single and multiple dose administration of 4 mg tizanidine showed that women concurrently taking oral contraceptives had 50% lower clearance of tizanidine than women not on oral contraceptives. Chemical IUPAC Name: 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-8-thia-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraen-5-amine : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |